Citi lowered the firm’s price target on Krystal Biotech (KRYS) to $155 from $215 and keeps a Neutral rating on the shares. The company’s Q1 report reinforced moderating U.S. Vyjuvek dynamics, the analyst tells investors in a research note. Citi lowered its peak U.S. Vyjuvek to $500M from $700M and peak global Vyjuvek sales estimate to $700M from $1B. The firm says that despite the share pullback, a Neutral rating remains appropriate on Krystal Biotech.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech’s Gene Therapy Expansion: Promising Preclinical Results and Long-term Value Proposition
- Krystal Biotech Expands Gene Therapy Platform
- Biotech Alert: Searches spiking for these stocks today
- Krystal Biotech price target lowered to $189 from $195 at Guggenheim
- Krystal Biotech: Buy Rating Amid Temporary Revenue Dip and Promising Growth Prospects